DBV Technologies S.A.

DBVT▼

DBV Technologies to raise approximately $50 million through at-the-market ADS sale to RA Capital

DBV Technologies announced it has agreed to sell new American Depositary Shares to RA Capital Management for total gross proceeds of approximately $50 million before commissions and expenses, through its at-the-market program on Nasdaq. The company will issue 18,288,220 new ordinary shares underlying 3,657,644 new ADSs at a price of $13.67 per ADS, with each ADS representing five ordinary shares. The issuance is expected to close on August 3, 2026, and the new ordinary shares will represent a dilution of approximately 5.82% upon completion. Citizens JMP Securities acted as sales agent for the transaction.

DBV.PA ▼

GlobeNewswire·50dRead more →

Biotech & Genomic Medicine▲

Food Allergy Market Valued at $2.7 Billion in 2025, Projected to Grow at 9.4% CAGR Through 2036

The food allergy market across the seven major markets was valued at approximately USD 2.7 billion in 2025 and is projected to expand at a robust CAGR of 9.4% through 2036, according to DelveInsight. The seven major markets comprise the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key approved therapies include peanut allergen powder (PALFORZIA), omalizumab (XOLAIR), and epinephrine nasal spray (NEFFY). The pipeline features several emerging therapies, including DBV Technologies' Viaskin Peanut Patch in Phase III, Novartis' remibrutinib in Phase II, Aravax's PVX108 in Phase II, GSK's ozureprubart in Phase II, and Aquestive Therapeutics' epinephrine sublingual film ANAPHYLM in Phase III. GSK strengthened its position through the acquisition of RAPT Therapeutics, gaining access to ozureprubart.

DBV.PA ▲AQST ▲GSK.LSE ▲NOVN.SW ▲

Biotech & Genomic Medicine ▲

PR Newswire·53dRead more →

DBVT

DBV Technologies Files ATM Prospectus for Up to $150 Million of ADS Sales

DBV Technologies has filed a new shelf registration statement with the SEC that includes a prospectus supplement refreshing its at-the-market offering program for up to $150 million of American Depositary Shares. The ATM program was established under a sales agreement dated September 5, 2025, with Citizens JMP Securities acting as sales agent, and the new filing carries forward unsold capacity together with additional newly registered capacity so that $150 million remains available for issuance. Each ADS represents five ordinary shares of the company. DBV Technologies intends to use any net proceeds primarily for manufacturing expansion, launch preparation of Viaskin Peanut in ages 4 through 7 if approved, development of product candidates, and working capital and general corporate purposes.

DBV.PA

GlobeNewswire·63dRead more →

DBVT

Netflix, Alcoa, and Five Others Report After-Hours Earnings on July 16

Seven companies are scheduled to report quarterly earnings after the market closes on July 16, 2026. Netflix is expected to post earnings per share of $0.79, a 9.72% increase from the same quarter last year, with a forward price-to-earnings ratio of 20.47. Alcoa's consensus forecast stands at $2.33 per share, a 497.44% surge year-over-year, though it missed estimates by 12.5% in the first quarter. F.N.B. Corporation is projected to earn $0.42 per share, up 16.67%, while Vista Energy's estimate of $3.15 represents a 472.73% jump. Independent Bank Corp. is expected to report $1.77 per share, a 41.60% increase, after a slight miss last quarter. Simmons First National Corporation's forecast is $0.53 per share, a 20.45% rise, and DBV Technologies is anticipated to narrow its loss to $0.12 per share, a 92.26% improvement.

AA DBV.PA FNB IBCP NFLX SFNC +1

Zacks·64dRead more →